Evaluation of coagulation parameters in patients with parathyroid adenoma

Murat Alay1*, Berrak Mermit Ercek2, Gulcin Miyase Sonmez2, Aysegul Sakin3, Rifki Ucler1 & Saliha Yildiz1

Parathyroid adenoma is responsible for 80–85% of cases of primary hyperparathyroidism. Increased fibrinogen levels in patients with adenoma may increase the risk of atherosclerosis and cardiovascular events. The aim of this study was to investigate the relationship between coagulation parameters and parathyroid adenoma. A prospective study included 28 female patients with parathyroid adenoma aged 40–88 years and 27 age-matched healthy controls. The coagulation parameters were assessed for each participant. The mean ages of the patient and control groups were 57.7 ± 10.9 and 53.3 ± 9.31 years, respectively. The mean level of protein S activity was 65.79 ± 13.78 in the patient group and 77.00 ± 15.72 in the control group, and the difference was statistically significant (p = 0.013). The mean fibrinogen levels of the patient and control groups were 338.78 ± 63.87 mg/dL and 304.30 ± 45.67 mg/dL, respectively, and a significant difference was found (p = 0.041). However, no significant difference was evident between the two groups with regard to the D-dimer (p = 0.238), aPTT (p = 0.645), INR (p = 0.406), protein C (p = 0.076), and AT-III (p = 0.180) levels. A positive correlation was observed between adenoma volume and fibrinogen in the patient group (r = 0.711, p = 0.001). The protein S levels were lower and the fibrinogen levels higher in the patients with parathyroid adenoma.

Primary hyperparathyroidism (PHPT) is a clinical condition characterized by autonomous secretions of parathyroid hormone (PTH)1. PHPT is the third most common endocrine disorder and the leading etiological cause of hypercalcemia in nonhospitalized patients. Although its peak incidence occurs in the fifth decade, PHPT can be seen in early ages as well. Its incidence is 2–3 times higher in women than in men2. Moreover, its incidence in postmenopausal women is 1:2003. Almost 80–85% of PHPT cases are caused by solitary parathyroid adenoma. The symptoms of PHPT associated with hypercalcemia include overt bone disease, kidney stones, and nonspecific gastrointestinal, cardiovascular, and neuromuscular dysfunction.

Hemostatic disturbances can be diagnosed by assessing the activated partial thromboplastin time (aPTT), international normalized ratio (INR), clotting time, and serum levels of protein C, protein S, and antithrombin 3 (AT-III)4. PHPT is typically accompanied by an increased risk of cardiovascular morbidity and mortality and has been shown to be associated with cardiovascular risk factors such as hypertension, dyslipidemia, and metabolic syndrome5. The coagulation abnormalities in PHPT have been reported in a limited number of case studies, and the results presented by the studies are unclear6,7. On the other hand, the coexistence of renal vein thrombosis and venous thrombosis-induced skin necrosis has been reported in patients with hyperparathyroidism7. PHPT has also been shown to be associated with increased factor VII (FVII), FX, D-dimer, and plasminogen activator-1 levels8.

The present study was designed to investigate the relationship between coagulation parameters and parathyroid adenoma.

Results

The study included a patient group of 28 women and a control group of 27 age-matched women. Table 1 presents the demographic characteristics of both groups. No significant differences were found between the two groups with regard to age and BMI. However, both the systolic and diastolic blood pressures were significantly higher in the patient group compared to the control group (p = 0.004 and p = 0.004, respectively) (Table 1).
The serum P (\(p = 0.001\)) and albumin (\(p = 0.018\)) levels were significantly lower in the patient group compared to the control group. In contrast, the PTH (\(p = 0.000\)) and Ca (\(p = 0.000\)) levels were significantly higher in the patient group compared to the control group. Table 2 presents the laboratory parameters of both groups (Table 2).

In the patient group, the protein S levels were significantly lower (\(p = 0.013\)) and the fibrinogen levels significantly higher (\(p = 0.041\)) compared to the control group. However, no significant difference was found between the two groups with regard to D-dimer (\(p = 0.238\)), aPTT (\(p = 0.645\)), INR (\(p = 0.406\)), protein C (\(p = 0.076\)), and AT-III (\(p = 0.180\)) levels (Table 2).

In the patient group, a bivariate analysis indicated a significantly positive correlation between adenoma volume and fibrinogen (\(r = 0.711, p = 0.001\)). Table 3 and Fig. 1 present the correlations determined in the patient group.

**Discussion**

Increased levels of fibrinogen in patients with parathyroid adenoma may pave the way for clotting and increase the risk of atherosclerotic and atherothrombotic complications since fibrinogen is an independent risk factor for cardiovascular disease. Accordingly, the present study aimed to investigate the relationship between coagulation parameters and hyperparathyroidism in patients diagnosed with parathyroid adenoma. The results indicated that
the fibrinogen levels were significantly higher and the protein S levels significantly lower in the patient group compared to the control group. Additionally, a bivariate analysis showed a significantly positive correlation between adenoma volume and fibrinogen in the patient group.

Elbers et al. evaluated 54 patients with hyperparathyroidism secondary to vitamin D deficiency and found no significant difference between the patients and control subjects with regard to PT, aPTT, fibrinogen, FVII, and FVIII levels. Yorulmaz et al. evaluated 25 patients with PHPT, 25 patients with secondary hyperthyroidism, and 25 healthy controls and revealed that the aPTT and D-dimer levels were significantly increased in the patients with secondary hyperthyroidism. Taken together, these findings seem highly controversial. In our study, no significant difference was found between the patient and control groups with regard to coagulation parameters, including D-dimer, aPTT, INR, protein C, and AT-III levels.

Increased fibrinogen levels are a major risk factor for cardiovascular disease. A prospective study conducted by the Northwick Park Heart Study in the United Kingdom evaluated a total of 1,511 male patients aged 40–64 years over a period of 10 years and reported that cardiovascular events were observed in 106 patients. The study also compared the groups with a mean fibrinogen level of 290 ± 59 mg/dL and those with a mean fibrinogen level of 315 ± 71 mg/dL and found a significant relationship between a high fibrinogen level and cardiovascular risk within the first 5-year follow-up period. The Atherosclerosis Risk in Communities study evaluated a total of 6,297 men and 8,180 women aged 45–64 years and reported that the mean fibrinogen levels were 295 ± 65 mg/dL and 320 ± 65 mg/dL in the men and 306 ± 65 mg/dL and 346 ± 65 mg/dL in the women over a mean follow-up period of 5.2 and 5.5 years, respectively. By comparing these values, the authors concluded that an increased fibrinogen level is a risk factor for cardiovascular disease.

In the Scottish Heart Health Study 1 (SHHS 1), SHHS 2, Fowkes, and MONICA studies conducted in Scotland, the relationship between fibrinogen and cardiovascular disease was investigated. The SHHS 1 examined 3,930 men and 3,760 women aged 40–59 years without cardiovascular disease, while the SHHS 2 examined 1,163 men and 1,102 women of the same age range with cardiovascular disease. At the end of the 8-year follow-up period, the men and women in the SHHS 1 had mean fibrinogen levels of 276 mg/dL and 287 mg/dL as opposed to 290 mg/dL and 311 mg/dL in the SHHS 2, respectively. Based on these values, the authors concluded that fibrinogen is an independent risk factor for cardiovascular disease. Likewise, a study conducted by European Concerted Action on Thrombosis and Disabilities and, separately, the Bezafibrate Infarction Prevention study obtained similar findings and also emphasized that fibrinogen is a risk factor for cardiovascular disease. The Prospective Cardiovascular Munster study and Gottingen Risk Incidence Prevalence Study in Germany similarly concluded that fibrinogen is an independent risk factor for cardiovascular disease. Moreover, numerous other studies have suggested that there is a significant relationship between increased plasma fibrinogen levels and cardiovascular events, including ischemic heart disease, peripheral artery disease, stroke, and deep vein thrombosis.

To our knowledge, no study in the literature has investigated the fibrinogen levels in patients with parathyroid adenoma. In our study, the fibrinogen levels were significantly higher in the patient group compared to the control group. Given that fibrinogen is an independent risk factor for cardiovascular disease, we suggest that clinicians keep atherosclerotic heart disease and cardiovascular complications in mind when treating patients with parathyroid adenoma.

In our study, the Ca and PTH levels and systolic blood pressure were found to be significantly higher in the patient group. A previous study evaluated the association between blood pressure and the incidence of cardiovascular disease using the Framingham Risk Score and suggested that individuals with a systolic pressure of

Figure 1. The correlation between adenoma value and fibrinogen levels.
deficiencies increase the risk of thromboembolism by 2–11 times when compared to the general population. Participants with an albumin level of less than 4 mg/dL, the total serum Ca was corrected for albumin using the measurement of PTH, calcium (Ca), phosphor (P), albumin, and UCa/Cr in spot urine samples. The measurement of routine biochemical parameters. Measurement of routine biochemical parameters. This prospective study included 30 female patients aged 19–88 years who were followed up in our endocrine diseases outpatient clinic due to parathyroid adenoma between February 2018 and December 2019. Pregnancy, oral contraceptive use, anticoagulant use, and a history of acute thromboembolism were defined as the exclusion criteria since they could have affected the coagulation parameters. Parathyroid adenoma was diagnosed based on serum calcium, phosphor, PTH, and albumin levels as well as parathyroid ultrasound (USG) examination and the urinary calcium/creatinine ratio (UCa/Cr) in spot urine samples. A control group that included 30 age-matched healthy women who presented to our endocrine diseases outpatient clinic and had no inherited or genetic diseases was also included in the study. This study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki. The University of Yüzüncü Yıl Investigational Review Board assessed the ethics of our procedures and approved our study (Project code: TTU-2019–8240, Date: September 11, 2019). All methods were carried out in accordance with the relevant directives and regulations, and informed consent was obtained from all the participants for the experiments. Measurement of routine biochemical parameters. The demographic characteristics, including age and body mass index (BMI), were recorded for each participant. Blood and urine samples were collected for the measurement of PTH, calcium (Ca), phosphor (P), albumin, and UCa/Cr in spot urine samples. The measurements were performed using an Architect Ci16200 autoanalyzer (Abbott Laboratories, Abbott Park, IL). For the participants with an albumin level of less than 4 mg/dL, the total serum Ca was corrected for albumin using the...
following formula: corrected Ca = total Ca + \(0.8 \times [4.0 – \text{albumin}]\). The UCa/Cr in the spot urine samples was calculated for each participant.

Venous blood samples were collected from each participant to measure the serum aPTT, D-dimer, fibrinogen, INR, protein C, protein S, and AT-III activity. The samples were placed in coagulation tubes containing a buffered 3.2% trisodium citrate solution and then promptly transferred to our Hematology Laboratory to assess the aPTT, D-dimer, INR, and fibrinogen activity. The measurements were performed using a STA Compact Ci6200 autoanalyzer (Diagnostica Stago, Inc., Parsippany, NJ) with commercially available kits, and the normal reference range of fibrinogen activity was accepted as 180–400 mg/dL and the normal reference range of D-dimer as 0–500 μg/L.

For the assessment of protein C, protein S, and AT-III activity, the blood samples were centrifuged at 3,000 rpm/min for 10 min, and the serum was then separated. The serum samples were stored at −20 °C until analysis (within 1–2 weeks) and analyzed using a STA Compact Ci6200 autoanalyzer with commercially available kits.

In the tests performed for the evaluation of AT-III, protein-S, and protein-C activity, the normal activity ranges were accepted as 75–125%, 60–123%, and 70–140%, respectively.

**Parathyroid USG.** A neck USG examination was performed for each patient in the patient group using the GE Logiq 7 USG system (GE Healthcare, Milwaukee, WI). The localization, volume (width × length × height × π/6), and the largest diameter of the adenomas detected on USG were recorded.

**Statistical analysis.** In our study, the planned sample size was at least 28 subjects, and the power analysis (power of a test) was calculated based on this sample. According to the results obtained for 28 subjects using the G’Power statistical program version 3.1.9.4 (Faul and Erdfelder, 1998), the power was calculated as 90%, the type 1 error was 5%, and the effect size was 0.8.

The data were analyzed using SPSS for Windows version 20.0 (IBM, Chicago, IL, USA). The continuous variables were expressed as mean, standard deviation, minimum, and maximum. The categorical variables were expressed as frequencies (n) and percentages (%). To determine whether the measurements in the study were normally distributed, the Shapiro–Wilk test (n < 50) was used, and it was observed that the measurements were normally distributed. The continuous variables were compared using a Student’s t-test, and the correlations between the continuous variables were determined using Pearson’s correlation coefficient. A p-value of <0.05 was considered significant.

**Institutional review board statement.** This study and all the relevant procedures were performed in accordance with the Declaration of Helsinki after obtaining ethical board approval from the Yüzüncü Yıl University Ethics Committee (Project code: TTU-2019-8240, Date: September 11, 2019).

Received: 15 April 2020; Accepted: 22 October 2020
Published online: 05 November 2020

**References**

1. Nakaoka, D. et al. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. *Endocrine J.* 47, 231–237 (2000).
2. Uysal, A. J. 2. baskı, Ankara, MN Medikal Nobel. Primer hiperparatiroidizm ve hiperkalsemi, sekonder hiperparatiroidizm. 295–302 (2005).
3. Rubin, M. R. *The dysfibrinogenaemias.* (Cambridge University Press, Cambridge, UK, 1978).
4. Campbell, F. W. The contribution of platelet dysfunction to postbypass bleeding. *Ann. Thorac. Surg.* 62, 1549–1557 (1996).
5. To, B. J. P. *The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.* *J. Clin. Endocrinol. Metab.* 93, 3462–3470 (2008).
6. Roberts, H. R., Stinchcombe, T. E. & Gabriel, D. A. J. The dysfibrinogenaemias. *Br. J. Haematol.* 114, 249–257 (2001).
7. Doyle, E. M. Jr., Verrier, E. D. & Spiess, B. D. J. T. Endothelial cell injury in cardiovascular surgery: the procoagulant response. *Ann. Thorac. Surg.* 62, 1549–1557 (1996).
8. Özarmağan, S. & Tezelman, S. J. G. K. Genel Cerrahi. *Primer hiperparatiroidizm ve hiperkalsemi, sekonder hiperparatiroidizm.* 295–302 (2005).
9. Elbers, L. P. et al. Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. *Endocr. Pract.* 7, 325–333 (2018).
10. Vora, L. F., Akalin, A. & Akay, M. In *15th International & 14th European Congress of Endocrinology,* (BioScientifica).
11. Meade, T. et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. *The Lancet* 328, 533–537 (1986).
12. Folsom, A. R., Wu, K. K., Rosamond, W. D., Sharrett, A. R. & Chambless, L. E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 96, 1102–1108 (1997).
13. Woodrow, M., Lowe, G., Rumley, A. & Tunstall-Pedoe, H. J. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: the Scottish Heart Health Study. *Eur. Heart J.* 19, 55–62 (1998).
14. Thompson, S. G., Kienast, J., Pyke, S. D., Haverkate, F. & van de Loo, J. C. J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. *N. Engl. J. Med.* 332, 635–641 (1995).
15. Benderly, M. et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. *Arterioscler. Thrombosis Vasc. Biol.* 16, 351–356 (1996).
16. Heinrich, J. et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. *Arterioscler. Thrombosis Vasc. Biol.* 16, 54–59 (1999).
17. Cremers, P. et al. Lipoprotein Lp (a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). *Eur. J. Clin. Investig.* 24, 444–453 (1994).
18. Vasan, R. S. et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N. Engl. J. Med.* 345, 1291–1297 (2001).
19. Douay, X., Lucas, C., Caron, C., Goudemand, J. & Leys, D. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. *Acta Neurol. Scand.* 98, 124–127 (1998).
20. Martinez, H. R., Rangel-Guerra, R. A. & Marfil, L. J. Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults. *Stroke* 24, 19–25 (1993).
21. Türan, O., Ündar, B., Günyay, T. & Akkoclu, A. Investigation of inherited thrombophilias in patients with pulmonary embolism. *Blood Coagul. Fibrinolysis* 24, 140–149 (2013).
22. Onderoglu, L. *et al.* High frequency of thromophilic disorders in women with recurrent fetal miscarriage. *Clin. Exp. Obstet. Gynecol.* 33, 50 (2006).
23. Furie, B. & Furie, B. C. Molecular and cellular biology of blood coagulation. *N. Engl. J. Med.* 326, 800–806 (1992).

**Acknowledgements**

The authors would like to thank the staff of the Yüzüncü Yıl University Medical Faculty endocrinology clinic for collecting the data.

**Author contributions**

Concept—M.A., B.M.E.; Design—M.A., G.M.S.; Supervision—A.S., R.U.; Resources—M.A., G.M.S.; Materials—B.M.E., G.M.S., S.Y.; Data Collection and/or Processing—A.S., R.U., S.Y.; Analysis and/or Interpretation—M.A., B.M.E., A.S.; Literature Search—M.A., B.M.E., R.U.; Writing Manuscript—M.A., B.M.E., G.M.S.; Critical Review—A.S., R.U.; Other—A.S., S.Y.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to M.A.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2020